Thu, Jul 24, 2014, 4:51 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Amgen, Inc. (AMGN) Message Board

  • cramerstrophywife cramerstrophywife Feb 8, 2012 9:15 AM Flag

    Briefing.com let's rock AMGN!!!

    8:07AM Amgen announced data for XGEVA to treat men with castration-resistant prostate cancer; data showed that XGEVA significantly reduced the risk for bone metastases or death by 15 percent and increased bone metastasis-free survival (AMGN) 69.18 : The primary analysis of the overall '147 study population showed that XGEVA significantly reduced the risk for bone metastases or death by 15 percent and increased bone metastasis-free survival, or the time a patient went without developing bone metastasis, by a median of 4.2 months. In exploratory analyses of patients with PSA doubling time of 10 months or less, XGEVA prolonged median bone metastasis-free survival time by 6.0 months compared with placebo with a 16 percent reduction in risk. In patients with PSA doubling time of 6 months or less, XGEVA prolonged median bone metastasis-free survival time by 7.2 months compared with placebo with a 23 percent reduction in risk. No new safety risks were identified in the study. Adverse events and serious adverse events were relatively similar between the XGEVA and placebo arms.

 
AMGN
122.26+0.25(+0.20%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.